Screener
Halozyme Therapeutics HALO Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $229.91M+39.2% | $150.05M+27.1% | —— | $175.23M+27.9% | $165.16M+77.1% | ||
| $4.5M+66.7% | $4.22M+57.1% | $3.3M+24.5% | $2.7M+3.8% | $2.7M+3.8% | ||
| $17.7M+45.5% | $16.64M+55.9% | $16.57M+44.6% | $12.16M-3.3% | $12.16M+28.4% | ||
| $240.89M+142% | $180.08M+16.8% | $219.03M+22.7% | $178.6M+54.8% | $99.71M+78.7% | ||
| $4.17M+167% | $3.74M+294% | $1.43M-53.2% | $3.03M+99.7% | $1.56M-39.5% | ||
| -$62.66M— | -$2.88M+96.8% | -$741.79M— | $201.61M+220% | —— | ||
| —— | —— | —— | $38.88M— | —— | ||
| -$326.25M-9.1% | -$1.61M+51.4% | —— | -$22.4M-221% | -$298.97M-3,253% | ||
| —— | $175.59M+190% | —— | $357.8M+1,167% | -$114.47M-593% | ||
| $236.72M+141% | $176.34M+15.0% | $217.6M+24.0% | $175.57M+54.2% | $98.15M+84.4% |
FAQ
- How much cash does Halozyme Therapeutics generate?
- Halozyme Therapeutics (HALO) generated $818.6M in operating cash flow over the trailing twelve months.
- What is Halozyme Therapeutics's free cash flow?
- After $12.4M of capital expenditures, Halozyme Therapeutics's free cash flow was $806.2M over the trailing twelve months, up 49.1% year over year.
- Where does Halozyme Therapeutics's cash flow data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
